Oral cancer is the sixth most common type of cancer worldwide and in the U.S., one person dies every hour from the disease. According to American Cancer Society data, nearly as many women will be diagnosed with oral cancer as with cervical cancer this year. The key to reducing the impact of this disease is early detection.
A new study demonstrates that vaccines may be less effective at countering the newer SARS-CoV-2 variants compared to natural infection.
The University at Buffalo has received a $1.5 million grant from the United States Department of Defense to develop new therapies that help reduce chronic inflammation and immunosuppression in oral cancers.
Professor Mark McGurk speaks to News-Medical about his groundbreaking research that has led to the discovery of a world-first treatment for oral cancer.
Discovering and treating tumors before they spread throughout the body is key for cancer patients to achieve positive outcomes. When tumor cells spread, which is known as metastasis, they can take over other organs and lead to death.
NYU Oral Cancer Center has been awarded a five-year, $3.1 million grant (R01 CA231396) by the National Cancer Institute (NCI), part of the National Institutes of Health (NIH).
A wide breadth of behaviors surrounding oral sex may affect the risk of oral HPV infection and of a virus-associated head and neck cancer that can be spread through this route, a new study led by researchers at the Johns Hopkins Kimmel Cancer Center suggests.
Researchers at Case Western Reserve University and partners in the United States and India are applying the investigative and predictive capabilities of artificial intelligence (AI) to help physicians customize treatments for patients with oral squamous cell carcinomas.
Affecting almost 600,000 people worldwide every year, and with only a 50% survival rate, oral squamous cell carcinoma (OSCC) is one of the more common and deadly forms of cancer.
Oral cancer is more likely to spread in patients experiencing high levels of pain, according to a team of researchers at New York University College of Dentistry that found genetic and cellular clues as to why metastatic oral cancers are so painful.
Mouth lesions are among the main early indicators of oral cancer, but determining whether a sore is actually malignant typically involves painful, costly biopsies.
Researchers at Trinity College Dublin have examined the sustainability of different models of the most commonly used oral health product - the toothbrush - to ascertain which is best for the planet and associated human health.
Researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute and The Ohio State University Wexner Medical Center are conducting a new clinical trial to determine if an oral cancer drug called ibrutinib can also help patients with cancer or other immunocompromised conditions recover from COVID-19.
Studying DNA mutations in cancers can help clarify how cancers develop and what makes cancer cells different from normal, healthy cells.
A new mobile app can help clinicians determine which patients with the novel coronavirus (COVID-19) are likely to have severe cases.
The June 2020 issue of Journal of Dental Research brings together a collection of the latest research on the oral microbiome.
The National Institute of Dental and Craniofacial Research (NIDCR), part of the National Institutes of Health, has awarded NYU College of Dentistry's Yi Ye, PhD, a $2.2 million, five-year grant to study the role of Schwann cells, the most prevalent type of cell supporting neurons in the peripheral nervous system, in oral cancer progression and pain.
Researchers at Okayama University have recently published a study in Cells in which they reduced the size of oral cancer tumors by damaging the blood vessels surrounding the tumor cells.
The ache in three of Kathy McCracken's teeth started almost four years ago. It was hard for her to chew and swallow. She was sensitive to both hot and cold food.
Loss of an important tumor-suppressing gene allows head and neck cancer to spin off signals to nearby nerves, changing their function and recruiting them to the tumor, where they fuel growth and cancer progression, researchers from The University of Texas MD Anderson Cancer Center report in the journal Nature today.
In a UCLA-led phase I clinical trial, a new plant-based drug called APG-157 showed signs of helping patients fight oral and oropharyngeal cancers. These cancers are located in the head and the neck.